RxDoctor Payments Data

Nafea Zayouna, MD

Gastroenterology · Warren, MINPI 1285968446

Payments from drug & device makers

$3,903in general payments, 2019–2025

Across 149 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$800
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$446
  • Cook Medical LLC$354
  • Bristol Myers Squibb$285
  • Takeda Pharmaceuticals U.S.A., Inc.$233
  • plus $752 from 16 others

What the payments were for

  • Food & beverage$3,71395%
  • Education$1905%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,903 in reported general payments places this provider in the 60th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$239,194
Medicare patients
719
Services billed
2,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$420,143
LinzessLinaclotide61$61,461
IbsrelaTenapanor Hcl19$41,186
Pantoprazole Sodium192$3,645
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl98$1,638
Omeprazole53$1,079
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl36$617
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine28$519
Ondansetron Hcl37$500
Levothyroxine Sodium38$417
Hydrocortisone18$351
Dicyclomine Hcl15$293
Lisinopril12$107
Metoprolol Tartrate12$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$800$420,14317 claims
AbbVieLinzess$1,032$61,46161 claims
Ardelyx, Inc.Ibsrela$13$41,18619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →